Eloxx Pharmaceuticals, Inc.

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that engages in the research and development of pharmaceutical therapies. The company focuses primarily on developing its lead drug candidate, exaluren, which is undergoing clinical evaluation. Operating through a unified research and development segment, Eloxx enters into collaborative agreements, research arrangements, and licensing partnerships to progress its drug candidates. Because its programs remain in development stages, the company currently interacts with strategic collaborators, research foundations, and commercial licensing partners, such as Almirall and the Cystic Fibrosis Foundation, rather than selling finished products directly to commercial healthcare providers.

The company is headquartered in Arlington, Massachusetts. Its operations and clinical research activities extend internationally, with operational ties and regulatory exposure across the United States, Israel, and Australia. Physical scale includes leased office premises alongside specialized facilities equipped with laboratory apparatus, computer systems, and related research infrastructure to support its development activities.

Summary of the business section of Eloxx Pharmaceuticals's latest annual report, written by StockData.

“As of December 31, 2025, we had seven employees in the United States and three employees in Israel.”